Verve Therapeutics Inc (VERV) concluded trading on Wednesday at a closing price of $5.47, with 4.57 million shares of worth about $25.02 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -3.19% during that period and on April 23, 2025 the price saw a gain of about 4.19%. Currently the company’s common shares owned by public are about 88.76M shares, out of which, 66.12M shares are available for trading.
Stock saw a price change of 10.06% in past 5 days and over the past one month there was a price change of -5.36%. Year-to-date (YTD), VERV shares are showing a performance of -3.01% which decreased to -17.62% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.86 but also hit the highest price of $9.31 during that period. The average intraday trading volume for Verve Therapeutics Inc shares is 2.64 million. The stock is currently trading 27.65% above its 20-day simple moving average (SMA20), while that difference is down -4.14% for SMA50 and it goes to -7.25% lower than SMA200.
Verve Therapeutics Inc (NASDAQ: VERV) currently have 88.76M outstanding shares and institutions hold larger chunk of about 70.02% of that.
The stock has a current market capitalization of $485.72M and its 3Y-monthly beta is at 1.69. It has posted earnings per share of -$2.35 in the same period. It has Quick Ratio of 12.65 while making debt-to-equity ratio of 0.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VERV, volatility over the week remained 14.29% while standing at 13.40% over the month.
Stock’s fiscal year EPS is expected to drop by -12.64% while it is estimated to increase by 0.62% in next year. EPS is likely to grow at an annualized rate of 6.26% for next 5-years, compared to annual growth of -42.43% made by the stock over the past 5-years.
Coverage by H.C. Wainwright stated Verve Therapeutics Inc (VERV) stock as a Buy in their note to investors on April 08, 2024, suggesting a price target of $15 for the stock. On April 13, 2023, Canaccord Genuity Initiated their recommendations, while on February 01, 2023, Cantor Fitzgerald Initiated their ratings for the stock with a price target of $21. Stock get a Sell rating from Goldman on December 15, 2022.
